CG Invites Co., Ltd. (KOSDAQ:083790)
1,006.00
+6.00 (0.60%)
Jun 30, 2026, 3:30 PM KST
CG Invites Revenue
CG Invites had revenue of 4.29B KRW in the quarter ending March 31, 2026, with 74.43% growth. This brings the company's revenue in the last twelve months to 29.22B, up 224.58% year-over-year. In the year 2025, CG Invites had annual revenue of 27.39B with 277.64% growth.
Revenue (ttm)
29.22B
Revenue Growth
+224.58%
P/S Ratio
2.63
Revenue / Employee
400.29M
Employees
73
Market Cap
76.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.39B | 20.14B | 277.64% |
| Dec 31, 2024 | 7.25B | 2.37B | 48.67% |
| Dec 31, 2023 | 4.88B | 557.33M | 12.90% |
| Dec 31, 2022 | 4.32B | -38.05B | -89.80% |
| Dec 31, 2021 | 42.38B | 12.15B | 40.21% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 199.60B |
| ORIENT BIO | 59.09B |
| Amicogen | 43.44B |
| GeneOne Life Science | 17.12B |
| Prestige BioPharma | 16.21B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| MedPacto | 4.79B |